Phase I study of novel gene therapy for HIV

November 06, 2006

GAITHERSBURG, MD - November 6, 2006 -VIRxSYS Corporation announced today the publication of results from their Phase I, open-label, non-randomized clinical trial evaluating VRX496, a gene-based immunotherapy for the treatment of HIV. Results of the Phase I trial conducted at the University of Pennsylvania School of Medicine were published today in the Proceedings of the National Academy of Sciences. The trial evaluated the safety and tolerability of VRX496, enrolling five subjects with chronic HIV infection who had failed to respond to at least two antiretroviral (ARV) drug regimens. Each of the five patients who tolerated the gene therapy treatment experienced decreases in viral load and experienced stable or increased CD4 T cell counts.

"Gene therapy has long been discussed as an alternative treatment to HIV," says senior author Carl June, MD, from Penn. "The results from this Phase I trial are encouraging--particularly since these are late-stage patients--and demonstrate that gene therapy has the potential to treat HIV and other serious human diseases."

VRX496, a CD4 T cell treatment against HIV, is the first application of VIRxSYS' lentiviral vector platform. It is the first, and continues to be the only, lentiviral vector currently administered in human clinical trials approved by the U.S. Food and Drug Administration. The backbone of VRX496 is an HIV-based lentiviral vector from which the disease-causing aspects of the virus have been removed, leaving behind an efficient gene-delivery vehicle. VIRxSYS then equips the vector with a long antisense sequence against the HIV envelope protein to create VRX496. Preclinical studies indicated that HIV is unable to mutate around VRX496's antisense therapy, thus the HIV is unable to form resistant strains in treated patients. VRX496 is transduced into a patient's own CD4 T cells to block HIV replication. Researchers believe this potentiates the immune response against HIV and restores normal immune function against other infections.

The Phase I trial demonstrated that a single intravenous infusion of autologous CD4 T cells genetically modified with VRX496 was safe and well tolerated. In addition to being monitored for adverse events over the course of the nine-month trial, subjects were also monitored for viral load, CD4 counts, immune response, and persistence of modified T cells. All patients had stable or decreased viral load, with three of the five patients exhibiting clinically significant reductions in viral load without changes in their ARV treatment at six months post infusion. Four of the five patients had stable or increased CD4 T cell counts. In addition, all five patients had stable or increased immune response to HIV antigens and other pathogens. Patients will have follow-up safety visits every year for 15 years. Some patients that have reached the three year post-infusion safety visit continue to exhibit persistence of modified cells, decreased viral load and increased CD4 counts over baseline.

"This is an important milestone in the development of what we believe will be the next-generation of HIV therapy," said Riku Rautsola, PhD, President and CEO of VIRxSYS. "VRX496 is engineered in a way that debilitates HIV's ability to replicate and mutate around the therapy, overcoming a common problem with current drug treatments. The treatment of diseases like cancer and HIV infection has been a distant promise, but the success of our team and other groups has shown that we are moving toward practical therapies. The results of this trial also contribute to the growing opinion that lentiviral vectors are the most promising viral vectors for clinical applications"

Two Phase II trials testing the safety and tolerability of single and repeated doses of VRX496 are underway. Preliminary results from these trials should be available in 2007. In preclinical and clinical studies, VRX496 has been able to deliver genes permanently, reproducibly and efficiently to human cells without toxicity or serious adverse events, such as immunogenicity or insertional oncogenesis (cancer), that plagued earlier gene therapy trials.

Founded in 1998, VIRxSYS is a private biotechnology company that develops therapies for serious diseases, such as HIV, cancer and genetic diseases, utilizing its novel lentiviral vector platform. The Company has exclusively licensed foundational technology from The Johns Hopkins University in Baltimore, Maryland, where the original research was conducted. The Company has developed additional patented technology relating to the application and manufacture of the lentiviral vector platform. More information regarding VIRxSYS can be found at Details on the ongoing Phase II clinical trials may be found at the NIH clinical trials website at


Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to